Blog

Designing better medicines using AI and big data

By its own definition, South By Southwest dedicates itself to helping creatives achieve their goals, and proves that the most unexpected discoveries happen when diverse topics and people come together.

And this is what brought our Benevolent Team to Texas - to share our collective vision of using the power of technology to solve something that truly matters to the world. For us this means tackling the most challenging and devastating diseases that currently have no cure, and we believe our efforts can and will change outcomes for patients.

In this video live from SXSW last month, our team of scientists and AI experts presented a ‘behind the scenes’ introduction to show how our latest advancements in machine learning and AI can better understand the underlying causes of diseases, and redefine the way in which new medicines are discovered and brought to patients.

At SXSW we used the example of Glioblastoma Multiforme, a very aggressive, currently incurable and most common form of brain cancer. We demonstrated something different and a little unconventional - the creative approach of how our team of BenevolentAI scientists, AI experts, engineers and chemists come together to try and solve such a complicated disease.

AI helps us uncover relationships between diseases and symptoms, drugs and their effect, the patients who respond to treatments and so much more. Relationships that would previously not have been uncovered due to the overwhelming volume of biomedical information and the inherent complexity of biology, diseases and the human body.

It’s too early to say if there will be an effective treatment for Glioblastoma any time soon. But every day, we improve our platform and increase the likelihood of finding a treatment. And we hope to return to SXSW to demonstrate the progress we are making on this devastating disease.

More Posts

You Might Also Like

News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
News
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Blog
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
News
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Video
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022
News
Notice of Interim Results and Analyst / Investor Event
BenevolentAI will announce interim results on the 27th of September and hold an analyst and investor event on the same day. Find out more.
Aug 26, 2022